가축용 백신 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Livestock Vaccines Market - Scope of Report

TMR's report on the global livestock vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global livestock vaccines market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global livestock vaccines market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the livestock vaccines market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global livestock vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global livestock vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global livestock vaccines market.

The report delves into the competitive landscape of the global livestock vaccines market. Key players operating in the global livestock vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global livestock vaccines market profiled in this report.

Key Questions Answered in Global livestock vaccines Market Report:

• What is the sales/revenue generated by livestock vaccines across all regions during the forecast period?
• What are the opportunities in the global livestock vaccines market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Livestock Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global livestock vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global livestock vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global livestock vaccines market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Livestock Vaccines Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Livestock Vaccines Market Analysis and Forecast, 2023-2031

5. Key Insights

• 5.1. Disease Epidemiology
• 5.2. Pipeline Analysis
• 5.3. Key Industry Events
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Livestock Vaccines Market Analysis and Forecast, by Vaccine Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Vaccine Type, 2023-2031
  • 6.3.1. Bovine Vaccine
  • 6.3.2. Poultry Vaccine
  • 6.3.3. Porcine Vaccine
  • 6.3.4. Others
• 6.4. Market Attractiveness Analysis, by Vaccine Type

7. Global Livestock Vaccines Market Analysis and Forecast, by Technology

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Technology, 2023-2031
  • 7.3.1. Live Attenuated Vaccine
  • 7.3.2. Inactivated Vaccine
  • 7.3.3. Recombinant Vaccine
  • 7.3.4. Others
• 7.4. Market Attractiveness Analysis, by Technology

8. Global Livestock Vaccines Market Analysis and Forecasts, by Route of Administration

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Route of Administration, 2023-2031
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Livestock Vaccines Market Analysis and Forecast, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by End-user, 2023-2031
  • 9.3.1. Veterinary Hospitals
  • 9.3.2. Veterinary Clinics
  • 9.3.3. Others
• 9.4. Market Attractiveness Analysis, by End-user

10. Global Livestock Vaccines Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2023-2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Country/Region

11. North America Livestock Vaccines Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Vaccine Type, 2023-2031
  • 11.2.1. Bovine Vaccine
  • 11.2.2. Poultry Vaccine
  • 11.2.3. Poultry Vaccine
  • 11.2.4. Others
• 11.3. Market Value Forecast, by Technology, 2023-2031
  • 11.3.1. Live Attenuated Vaccine
  • 11.3.2. Inactivated Vaccine
  • 11.3.3. Recombinant Vaccine
  • 11.3.4. Others
• 11.4. Market Value Forecast, by Route of Administration, 2023-2031
  • 11.4.1. Oral
  • 11.4.2. Parenteral
  • 11.4.3. Others
• 11.5. Market Value Forecast, by End-user, 2023-2031
  • 11.5.1. Veterinary Hospitals
  • 11.5.2. Veterinary Clinics
  • 11.5.3. Others
• 11.6. Market Value Forecast, by Country, 2023-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Vaccine Type
  • 11.7.2. By Technology
  • 11.7.3. By Route of Administration
  • 11.7.4. By End-user
  • 11.7.5. By Country/Sub-region

12. Europe Livestock Vaccines Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Vaccine Type, 2023-2031
  • 12.2.1. Bovine Vaccine
  • 12.2.2. Poultry Vaccine
  • 12.2.3. Porcine Vaccine
  • 12.2.4. Others
• 12.3. Market Value Forecast, by Technology, 2023-2031
  • 12.3.1. Live Attenuated Vaccine
  • 12.3.2. Inactivated Vaccine
  • 12.3.3. Recombinant Vaccine
  • 12.3.4. Others
• 12.4. Market Value Forecast, by Route of Administration, 2023-2031
  • 12.4.1. Oral
  • 12.4.2. Parenteral
  • 12.4.3. Others
• 12.5. Market Value Forecast, by End-user, 2023-2031
  • 12.5.1. Veterinary Hospitals
  • 12.5.2. Veterinary Clinics
  • 12.5.3. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Vaccine Type
  • 12.7.2. By Technology
  • 12.7.3. By Route of Administration
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Livestock Vaccines Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Vaccine Type, 2023-2031
  • 13.2.1. Bovine Vaccine
  • 13.2.2. Poultry Vaccine
  • 13.2.3. Porcine Vaccine
  • 13.2.4. others
• 13.3. Market Value Forecast, by Technology, 2023-2031
  • 13.3.1. Live Attenuated Vaccine
  • 13.3.2. Inactivated Vaccine
  • 13.3.3. Recombinant Vaccine
  • 13.3.4. Others
• 13.4. Market Value Forecast, by Route of Administration, 2023-2031
  • 13.4.1. Oral
  • 13.4.2. Parenteral
  • 13.4.3. Others
• 13.5. Market Value Forecast, by End-user, 2023-2031
  • 13.5.1. Veterinary Hospitals
  • 13.5.2. Veterinary Clinics
  • 13.5.3. Others
• 13.6. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Vaccine Type
  • 13.7.2. By Technology
  • 13.7.3. By Route of Administration
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Livestock Vaccines Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Vaccine Type, 2023-2031
  • 14.2.1. Bovine Vaccine
  • 14.2.2. Poultry Vaccine
  • 14.2.3. Porcine Vaccine
  • 14.2.4. Others Vaccine
• 14.3. Market Value Forecast, by Technology, 2023-2031
  • 14.3.1. Live Attenuated Vaccine
  • 14.3.2. Inactivated Vaccine
  • 14.3.3. Recombinant Vaccine
  • 14.3.4. Others
• 14.4. Market Value Forecast, by Route of Administration, 2023-2031
  • 14.4.1. Oral
  • 14.4.2. Parenteral
  • 14.4.3. Others
• 14.5. Market Value Forecast, by End-user, 2023-2031
  • 14.5.1. Veterinary Hospitals
  • 14.5.2. Veterinary Clinics
  • 14.5.3. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Vaccine Type
  • 14.7.2. By Technology
  • 14.7.3. By Route of Administration
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Livestock Vaccines Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Vaccine Type, 2023-2031
  • 15.2.1. Bovine Vaccine
  • 15.2.2. Poultry Vaccine
  • 15.2.3. Porcine Vaccine
  • 15.2.4. Others
• 15.3. Market Value Forecast, by Technology, 2023-2031
  • 15.3.1. Live Attenuated Vaccine
  • 15.3.2. Inactivated Vaccine
  • 15.3.3. Recombinant Vaccine
  • 15.3.4. Others
• 15.4. Market Value Forecast, by Route of Administration, 2023-2031
  • 15.4.1. Oral
  • 15.4.2. Parenteral
  • 15.4.3. Others
• 15.5. Market Value Forecast, by End-user, 2023-2031
  • 15.5.1. Veterinary Hospitals
  • 15.5.2. Veterinary Clinics
  • 15.5.3. Others
• 15.6. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Vaccine Type
  • 15.7.2. By Technology
  • 15.7.3. By Route of Administration
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2022)
• 16.3. Company Profiles
  • 16.3.1. Dechra Pharmaceuticals PLC
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. Ceva Sante Animale
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. Elanco
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Merck & Co., Inc.
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Zoetis Services LLC
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Boehringer Ingelheim International GmbH.
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. Virbac
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Biogenesis Bago
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. Ourofino Saude Animal
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview
  • 16.3.10. VETAL Animal Health Products, Inc.
    • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.10.2. Product Portfolio
    • 16.3.10.3. Financial Overview
    • 16.3.10.4. SWOT Analysis
    • 16.3.10.5. Strategic Overview
  • 16.3.11. Other prominent Players
    • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.11.2. Product Portfolio
    • 16.3.11.3. Financial Overview
    • 16.3.11.4. SWOT Analysis
    • 16.3.11.5. Strategic Overview